ATM and non-small cell lung carcinoma: Logistic regression analysis revealed that ATM expression is a significant predictor of treatment response in patients with metastatic NSCLC receiving pembrolizumab-based therapy, i.e., patients with high ATM expression had a significantly lower likelihood of responding to treatment (OR: 0.06; p = 0.006; 95% CI: 0.008–0.45).